It has been revealed what is the greatest threat to big pharma indemnity. Check out the latest reports about the matter below.
The greatest threat to big pharma
The greatest threat to Big Pharma’s indemnity is the DNA contamination in the vaccines.
The FDA claims there is nothing to see here. That is correct only because Pfizer avoided doing any genotoxicity and integration studies.
Dr Robert Malone is shocked by the FDA’s claim that contamination is not an issue when the dangers are well known to all experts in the field.
Highlighted by the fact that Moderna promoted its RNA patent on the basis it would overcome the dangers of DNA in vaccines.
The greatest threat to Big Pharma indemnity is the DNA contamination in the vaccines.
The FDA claim there is nothing to see here. That is correct only because Pfizer avoided doing any genotoxicity and integration studies.
Dr Robert Malone is shocked by the FDA claim that… pic.twitter.com/F5lKEptt0D
— Kat A 🌸 (@SaiKate108) November 14, 2023
Here is another relevant tweet about the matter:
True – and Canada Health experts are acknowledging it in a moment of clarity but then continues to fall for the bigpHARMa money and propaganda. https://t.co/IqW5oXYAs2
— René de Vries (@AafkodeVries) November 14, 2023
Someone commented the following: “Correction: Promoter not Inhibitor. Increase of Cancers Globally, which Dr’s have referred to as ‘Turbo Cancers’. The Dr.’s that spoke up were vilified and faced litigation abuse.”
It’s important to note that the phases of FDA approval are designed to ensure the safety and efficacy of drugs and vaccines. This rigorous process involves several stages, each crucial for assessing the potential risks and benefits. Understanding these phases helps to appreciate the complexity and importance of thorough drug and vaccine evaluation.
Covid vaccines in the news
According to an investigation by the British Medical Journal (BMJ), two high-level regulatory officials at the US Food and Drug Administration (FDA) who were responsible for vaccine oversight joined Moderna just a few months after approving the company’s COVID-19 vaccine for licensure.
The report by Peter Doshi, senior editor at The BMJ and associate professor at the University of Maryland School of Pharmacy, highlights the persistent revolving door between pharmaceutical companies regulated by the FDA and the agency’s top officials.
This raises concerns about the impartiality and independence of the FDA’s regulatory decision-makers. Check out our previous article in order to learn more details.
